Mostrando 7 resultados de: 7
Filtros aplicados
Publisher
Pharmacogenomics(2)
Clinical Pharmacology and Therapeutics(1)
Clinical Therapeutics(1)
Drug Metabolism and Drug Interactions(1)
Molecular Biology Reports(1)
Área temáticas
Farmacología y terapéutica(6)
Bioquímica(3)
Medicina y salud(3)
Genética y evolución(2)
Biología(1)
Origen
scopus(7)
Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting
ArticleAbstract: Purpose: The symposium Health and Medicines in Indigenous Populations of America was organized by thPalabras claves:CIOMS-RIBEF, clinical research, pharmacogenetics, resource-limited settingsAutores:Adrián LLerena, Diwakar S., Enrique Terán, Galaviz-Hernandez C., Gil J.P., Isabel Hernández, Lara-Riegos J., Molina-Guarneros J.A., Moya G.E., Nair S., Penãs-Lledó E.M., Rägo L., Ramírez-Roa R., Sosa-Macías M.G., Tarazona-Santos E.M., Verde I.Fuentes:googlescopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and pbkp_redicted phenotypes inPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusInterethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations
ArticleAbstract: UDP-glucuronosyltransferase 1A4 (UGT1A4) is a phase II drug-metabolizing enzyme that catalyzes the gPalabras claves:Glucuronidation, Interethnic differences, Mexican-Mestizo, Spaniards, UGT1A4Autores:Adrián LLerena, Alonso M.E., Cobaleda J., Dorado P., Gallego-Aguilera A., López M.L., MELANIE BRIGETTE ARROYO LOPEZ, Monroy-Jaramillo N., Ortega A., Penãs-Lledó E.M., Silva-Zolezzi I.Fuentes:googlescopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusPharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine
ReviewAbstract: Patients treated with antiepileptic drugs can exhibit large interindividual variability in clinicalPalabras claves:antiepileptic drug, Cytochrome p450, lamotrigine, pharmacogenetics, Phenytoin, UDP-glucuronosyltransferase (UGT)Autores:Adrián LLerena, Dorado P., ElisaAlonso M., Jung-Cook H., López M.L., Machín E., MELANIE BRIGETTE ARROYO LOPEZ, Monroy-Jaramillo N., Penãs-Lledó E.M.Fuentes:googlescopusRelationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers
ArticleAbstract: Aim: The CYP2C9 IVS8-109T allele was recently found to be more frequent among Swedish individuals, wPalabras claves:CYP2C9, intronic polymorphism, IVS8-109A>T, LOSARTÁNAutores:Adrián LLerena, Dorado P., Enrique Terán, Gallego A., Penãs-Lledó E.M.Fuentes:googlescopusPopulation pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014)
Conference ObjectAbstract: MESTIFAR 2014 28-30 November 2014, Panama City, Panama The CEIBA consortium was created within the IPalabras claves:Cytochrome p450, drug metabolism, genome-wide analyses, Ibero-Americans populations, Metabolic phenotypes, next-generation sequencing, pharmacogenetics, Population geneticsAutores:Acosta H., Adrián LLerena, Céspedes-Garro C., Enrique Terán, Galaviz-Hernandez C., Moya G.E., Penãs-Lledó E.M., Ramirez R., Sosa-Macías M.G., Tarazona-Santos E.M.Fuentes:googlescopus